NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Genenta Science S.p.A. (GNTA) Stock Analysis

Genenta Science S.p.A. (GNTA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GNTA

$0.96

+$0.01 (+0.95%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GNTA with… →

GNTA Key Statistics

As of Sep 4, 2026
Trading
Open
$0.94
Previous Close
$0.95
Day's Range
0.94–0.99
52-Week Range
0.55–10.00
Volume
31.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.72
Valuation
Market Cap
$46.29M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.39
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$6.53M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.22M
1-Year Return
−72.57%
Dividend and dates
Avg Volume
141.10K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GNTA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−35.57%
2025−65.75%
2024−12.12%
2023−10.00%
2022−49.83%
2021 (partial year)−0.35%

As of September 4, 2026.

GNTA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$6.53M—
2024$0.00−$8.91M—
2023$0.00−$11.65M—
2022$0.00−$8.48M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$6.60M−$6.53M—
2024$0.00—−$9.76M−$8.91M—
2023$0.00—−$11.73M−$11.65M—
2022$0.00—−$11.04M−$8.48M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GNTA Valuation vs Biotechnology Median

Median of 656 stocks
MetricGNTABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Genenta Science S.p.A. (GNTA) carries a market capitalisation of $46.29M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 9 employees.

GNTA last closed at $0.96 on September 4, 2026. That is +$0.01 (+0.95%) against the previous close. Over the past 52 weeks the price has ranged from $0.55 to $10.00. The latest close sits 74.55% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $6.53M. Profit margin runs at 0%. Trailing earnings per share are −0.39.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −72.57%. Across 3 years the annualized return works out at −44.15%. The reported beta is 0.72. Annualized volatility over the trailing 4 years is 107.32%.

Growth & Income

The record shows no dividend for GNTA.

Across the complete calendar years on file, 2023 returned −10.00% and 2025 returned −65.75%. Of the 4 complete calendar years on file, 0 finished higher. So far in 2026 the price is −35.57%.

Peer Comparison

Genenta Science S.p.A. (GNTA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Genenta Science S.p.A. GNTA $46.29M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Genenta Science S.p.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Genenta Science S.p.A.

Genenta Science S.p.A., develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Additionally it designs, engineers and manufactures high-precision tactical rifles, chassis systems, optics mounts, bipods, and related accessories. It also builds critical mechanical components for space and defense systems. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Visit website →